BMS-986368
AssetSmall molecule
Dual FAAH and MAGL inhibitor elevating endocannabinoid levels to reduce spasticity
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- Indications
- 3
- Trials
- 2
- Developers
- 2
Indications
3Agitation
Phase 2RECRUITINGNCT06808984clinicaltrials.gov7 Oct 2026
Alzheimer's disease
Phase 2RECRUITINGNCT06808984clinicaltrials.gov7 Oct 2026
Post-stroke spasticity
Phase 2RECRUITINGNCT07704840clinicaltrials.gov7 Oct 2026
- Targets and what it contains4
- Owner and partners2
- Trials2
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources